Affluent Medical SA
Affluent Medical SA (AFME.PA) Stock Competitors & Peer Comparison
See (AFME.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AFME.PA | €2.81 | +0.00% | 110.4M | -7.81 | -€0.36 | N/A |
| PHIA.AS | €23.58 | +1.03% | 22.5B | 25.38 | €0.93 | +3.60% |
| IBAB.BR | €12.64 | -2.62% | 383.9M | 30.47 | €0.43 | +1.83% |
| ALERS.PA | €22.50 | +9.22% | 214M | 96.59 | €0.22 | N/A |
| ALMDT.PA | €4.55 | +0.22% | 174.6M | -4.00 | -€1.16 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| EAPI.PA | €1.26 | -3.60% | 123.8M | -0.99 | -€1.31 | N/A |
| GBT.PA | €9.08 | -5.71% | 117.2M | -1.04 | -€8.91 | N/A |
| SEQUA.BR | €0.50 | +3.63% | 40.6M | -0.43 | -€1.23 | N/A |
| ALIMP.PA | €0.22 | +7.35% | 31.9M | -7.40 | -€0.03 | N/A |
Stock Comparison
AFME.PA vs PHIA.AS Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, PHIA.AS has a market cap of 22.5B. Regarding current trading prices, AFME.PA is priced at €2.81, while PHIA.AS trades at €23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas PHIA.AS's P/E ratio is 25.38. In terms of profitability, AFME.PA's ROE is -0.57%, compared to PHIA.AS's ROE of +0.08%. Regarding short-term risk, AFME.PA is more volatile compared to PHIA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check PHIA.AS's competition here
AFME.PA vs IBAB.BR Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, IBAB.BR has a market cap of 383.9M. Regarding current trading prices, AFME.PA is priced at €2.81, while IBAB.BR trades at €12.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas IBAB.BR's P/E ratio is 30.47. In terms of profitability, AFME.PA's ROE is -0.57%, compared to IBAB.BR's ROE of +0.10%. Regarding short-term risk, AFME.PA is more volatile compared to IBAB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check IBAB.BR's competition here
AFME.PA vs ALERS.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALERS.PA has a market cap of 214M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALERS.PA trades at €22.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALERS.PA's P/E ratio is 96.59. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALERS.PA's ROE of +0.01%. Regarding short-term risk, AFME.PA is more volatile compared to ALERS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALERS.PA's competition here
AFME.PA vs ALMDT.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALMDT.PA has a market cap of 174.6M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALMDT.PA trades at €4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALMDT.PA's P/E ratio is -4.00. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALMDT.PA's ROE of +0.59%. Regarding short-term risk, AFME.PA is more volatile compared to ALMDT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALMDT.PA's competition here
AFME.PA vs ALCOR.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, AFME.PA is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALCOR.PA's competition here
AFME.PA vs EAPI.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, EAPI.PA has a market cap of 123.8M. Regarding current trading prices, AFME.PA is priced at €2.81, while EAPI.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas EAPI.PA's P/E ratio is -0.99. In terms of profitability, AFME.PA's ROE is -0.57%, compared to EAPI.PA's ROE of -0.24%. Regarding short-term risk, AFME.PA is more volatile compared to EAPI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check EAPI.PA's competition here
AFME.PA vs GBT.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, GBT.PA has a market cap of 117.2M. Regarding current trading prices, AFME.PA is priced at €2.81, while GBT.PA trades at €9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas GBT.PA's P/E ratio is -1.04. In terms of profitability, AFME.PA's ROE is -0.57%, compared to GBT.PA's ROE of -0.34%. Regarding short-term risk, AFME.PA is more volatile compared to GBT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check GBT.PA's competition here
AFME.PA vs SEQUA.BR Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, SEQUA.BR has a market cap of 40.6M. Regarding current trading prices, AFME.PA is priced at €2.81, while SEQUA.BR trades at €0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas SEQUA.BR's P/E ratio is -0.43. In terms of profitability, AFME.PA's ROE is -0.57%, compared to SEQUA.BR's ROE of +1.24%. Regarding short-term risk, AFME.PA is more volatile compared to SEQUA.BR. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check SEQUA.BR's competition here
AFME.PA vs ALIMP.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALIMP.PA has a market cap of 31.9M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALIMP.PA trades at €0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALIMP.PA's P/E ratio is -7.40. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALIMP.PA's ROE of +13.76%. Regarding short-term risk, AFME.PA is more volatile compared to ALIMP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALIMP.PA's competition here
AFME.PA vs MKEA.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, AFME.PA is priced at €2.81, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, AFME.PA's ROE is -0.57%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, AFME.PA is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check MKEA.PA's competition here
AFME.PA vs ALNOV.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALNOV.PA has a market cap of 27.5M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALNOV.PA trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALNOV.PA's P/E ratio is -0.81. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALNOV.PA's ROE of -0.15%. Regarding short-term risk, AFME.PA is more volatile compared to ALNOV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALNOV.PA's competition here
AFME.PA vs ALDMS.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALDMS.PA has a market cap of 26.5M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALDMS.PA trades at €1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALDMS.PA's P/E ratio is -9.77. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALDMS.PA's ROE of -0.13%. Regarding short-term risk, AFME.PA is more volatile compared to ALDMS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALDMS.PA's competition here
AFME.PA vs ALIKO.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALIKO.PA has a market cap of 22.7M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALIKO.PA trades at €1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALIKO.PA's P/E ratio is -6.26. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, AFME.PA is more volatile compared to ALIKO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALIKO.PA's competition here
AFME.PA vs ALTHE.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALTHE.PA has a market cap of 20.8M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALTHE.PA trades at €0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALTHE.PA's P/E ratio is -4.00. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALTHE.PA's ROE of +4.68%. Regarding short-term risk, AFME.PA is more volatile compared to ALTHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALTHE.PA's competition here
AFME.PA vs ALTER.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, AFME.PA is more volatile compared to ALTER.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALTER.PA's competition here
AFME.PA vs ALEMG.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALEMG.PA has a market cap of 13.9M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALEMG.PA trades at €4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALEMG.PA's P/E ratio is 12.89. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALEMG.PA's ROE of -0.33%. Regarding short-term risk, AFME.PA is more volatile compared to ALEMG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALEMG.PA's competition here
AFME.PA vs ALBLU.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALBLU.PA has a market cap of 9M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALBLU.PA trades at €0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALBLU.PA's P/E ratio is -8.17. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALBLU.PA's ROE of -0.71%. Regarding short-term risk, AFME.PA is more volatile compared to ALBLU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALBLU.PA's competition here
AFME.PA vs ALSGD.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALSGD.PA has a market cap of 7.1M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALSGD.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALSGD.PA's P/E ratio is -2.87. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALSGD.PA's ROE of -0.63%. Regarding short-term risk, AFME.PA is more volatile compared to ALSGD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALSGD.PA's competition here
AFME.PA vs ALCAR.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, ALCAR.PA has a market cap of 6.4M. Regarding current trading prices, AFME.PA is priced at €2.81, while ALCAR.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas ALCAR.PA's P/E ratio is -0.09. In terms of profitability, AFME.PA's ROE is -0.57%, compared to ALCAR.PA's ROE of +1.07%. Regarding short-term risk, AFME.PA is more volatile compared to ALCAR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check ALCAR.PA's competition here
AFME.PA vs VMGBS.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, VMGBS.PA has a market cap of 0. Regarding current trading prices, AFME.PA is priced at €2.81, while VMGBS.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas VMGBS.PA's P/E ratio is N/A. In terms of profitability, AFME.PA's ROE is -0.57%, compared to VMGBS.PA's ROE of N/A. Regarding short-term risk, AFME.PA is more volatile compared to VMGBS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check VMGBS.PA's competition here
AFME.PA vs DGM.PA Comparison April 2026
AFME.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AFME.PA stands at 110.4M. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, AFME.PA is priced at €2.81, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AFME.PA currently has a P/E ratio of -7.81, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, AFME.PA's ROE is -0.57%, compared to DGM.PA's ROE of -0.23%. Regarding short-term risk, AFME.PA is more volatile compared to DGM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for AFME.PA.Check DGM.PA's competition here